Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

Joseph E. Blaney, Christoph Wirblich, Amy B. Papaneri, Reed F. Johnson, Carey J. Myers, Terry L. Juelich, Michael R. Holbrook, Alexander Freiberg, John G. Bernbaum, Peter B. Jahrling, Jason Paragas, Matthias J. Schnell

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.

Original languageEnglish (US)
Pages (from-to)10605-10616
Number of pages12
JournalJournal of Virology
Volume85
Issue number20
DOIs
StatePublished - Oct 2011

Fingerprint

Ebolavirus
Rabies virus
Attenuated Vaccines
live vaccines
Zaire Ebola virus
Inactivated Vaccines
vaccines
Ebola Vaccines
Glycoproteins
Vaccines
Rabies Vaccines
glycoproteins
inactivated vaccines
Human Parvovirus B19
Viruses
Reverse Genetics
mice
vaccination
Licensure
Humoral Immunity

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Blaney, J. E., Wirblich, C., Papaneri, A. B., Johnson, R. F., Myers, C. J., Juelich, T. L., ... Schnell, M. J. (2011). Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Journal of Virology, 85(20), 10605-10616. https://doi.org/10.1128/JVI.00558-11

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. / Blaney, Joseph E.; Wirblich, Christoph; Papaneri, Amy B.; Johnson, Reed F.; Myers, Carey J.; Juelich, Terry L.; Holbrook, Michael R.; Freiberg, Alexander; Bernbaum, John G.; Jahrling, Peter B.; Paragas, Jason; Schnell, Matthias J.

In: Journal of Virology, Vol. 85, No. 20, 10.2011, p. 10605-10616.

Research output: Contribution to journalArticle

Blaney, JE, Wirblich, C, Papaneri, AB, Johnson, RF, Myers, CJ, Juelich, TL, Holbrook, MR, Freiberg, A, Bernbaum, JG, Jahrling, PB, Paragas, J & Schnell, MJ 2011, 'Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses', Journal of Virology, vol. 85, no. 20, pp. 10605-10616. https://doi.org/10.1128/JVI.00558-11
Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Journal of Virology. 2011 Oct;85(20):10605-10616. https://doi.org/10.1128/JVI.00558-11
Blaney, Joseph E. ; Wirblich, Christoph ; Papaneri, Amy B. ; Johnson, Reed F. ; Myers, Carey J. ; Juelich, Terry L. ; Holbrook, Michael R. ; Freiberg, Alexander ; Bernbaum, John G. ; Jahrling, Peter B. ; Paragas, Jason ; Schnell, Matthias J. / Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. In: Journal of Virology. 2011 ; Vol. 85, No. 20. pp. 10605-10616.
@article{caf0a1e79040491eb7161aa39dd590e8,
title = "Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses",
abstract = "The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.",
author = "Blaney, {Joseph E.} and Christoph Wirblich and Papaneri, {Amy B.} and Johnson, {Reed F.} and Myers, {Carey J.} and Juelich, {Terry L.} and Holbrook, {Michael R.} and Alexander Freiberg and Bernbaum, {John G.} and Jahrling, {Peter B.} and Jason Paragas and Schnell, {Matthias J.}",
year = "2011",
month = "10",
doi = "10.1128/JVI.00558-11",
language = "English (US)",
volume = "85",
pages = "10605--10616",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "20",

}

TY - JOUR

T1 - Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

AU - Blaney, Joseph E.

AU - Wirblich, Christoph

AU - Papaneri, Amy B.

AU - Johnson, Reed F.

AU - Myers, Carey J.

AU - Juelich, Terry L.

AU - Holbrook, Michael R.

AU - Freiberg, Alexander

AU - Bernbaum, John G.

AU - Jahrling, Peter B.

AU - Paragas, Jason

AU - Schnell, Matthias J.

PY - 2011/10

Y1 - 2011/10

N2 - The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.

AB - The search for a safe and efficacious vaccine for Ebola virus continues, as no current vaccine candidate is nearing licensure. We have developed (i) replication-competent, (ii) replication-deficient, and (iii) chemically inactivated rabies virus (RABV) vaccines expressing Zaire Ebola virus (ZEBOV) glycoprotein (GP) by a reverse genetics system based on the SAD B19 RABV wildlife vaccine. ZEBOV GP is efficiently expressed by these vaccine candidates and is incorporated into virions. The vaccine candidates were avirulent after inoculation of adult mice, and viruses with a deletion in the RABV glycoprotein had greatly reduced neurovirulence after intracerebral inoculation in suckling mice. Immunization with live or inactivated RABV vaccines expressing ZEBOV GP induced humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. The bivalent RABV/ZEBOV vaccines described here have several distinct advantages that may speed the development of inactivated vaccines for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at risk of EBOV infection in endemic areas.

UR - http://www.scopus.com/inward/record.url?scp=80055058700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055058700&partnerID=8YFLogxK

U2 - 10.1128/JVI.00558-11

DO - 10.1128/JVI.00558-11

M3 - Article

VL - 85

SP - 10605

EP - 10616

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 20

ER -